This announcement is a separate document:
邁博藥業-B：(1) 有關收購CMAB807之須予披露及關連交易 (2) 有關臨床試驗協議及CDMO協議之持續關連交易 及 (3) 股東特別大會通告
MABPHARM-B: (1) DISCLOSEABLE AND CONNECTED TRANSACTION IN RELATION TO THE ACQUISITION OF CMAB807 (2) CONTINUING CONNECTED TRANSACTIONS IN RELATION TO THE CLINICAL TRIALS AGREEMENT AND THE CDMO AGREEMENTAND (3) NOTICE OF EXTRAORDINARY GENERAL MEETING
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.